Volume 7 Supplement 1

International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour

Open Access

Diabetes and atypical antipsychotics

  • Christos Istikoglou1,
  • Ochanes Mikirditsian1,
  • Constantinos Michelidakis1,
  • George Golfinopoulos1,
  • Maria Stathaki1 and
  • Demetrios Vlissides1
Annals of General Psychiatry20087(Suppl 1):S105

https://doi.org/10.1186/1744-859X-7-S1-S105

Published: 17 April 2008

Background

Atypical antipsychotic medicines are highly advanced compared to older classical antipsychotic factors. However, newer factors have been recently associated with other side effects, such as hyperglycemia, diabetes, increase of the body's weight and abnormal levels of lipids.

Even more alarming, due to high death risks, were numerous reports from patients, who were under treatment with Clozapine or Olanzapine. These patients developed diabetic cetoxin soon after starting taking these medicines.

The aim of this essay is to prove whether atypical antipsychotics are associated with the appearance of diabetes, increase of the body's weight and abnormal levels of lipids, or not.

Materials and methods

102 patients have been studied. They were treated with atypical antipsychotics and they had normal weight, blood diabetes level, and serum lipids, at the beginning of their treatment. They suffered either from Schizophrenia mostly, or from Bipolar Emotional Disorder. These patients were taking Risperidone, Olanzapine, Clozapine, Quetiapine, Amisoulpiride, Ziprasidone and Aripripazole.

Six months after the beginning of the treatment with these particular antipsychotics, the patients' weight, their diabetes level and the number of their serum lipids were measured.

Results

12 of the patients had symptoms concerning their blood diabetes. It was at a higher level. 6 of them were taking Clozapine, 4 of them Olanzapine, one aripripazole and one Risperidone. 37 other patients gained weight, 22 of which were taking Olanzapine, 9 Clozapine, 5 Risperidone, and one Quetiapine. 22 other patients had an increase at their serum lipids' level. 11 of them were taking Olanzapine, 5 Clozapine, 4 Risperidone, one Quetiapine and one Amisoulpiride.

Conclusions

It seems that almost all atypical antipsychotics and mostly Clozapine and Olanzapine can cause increase of the blood diabetes level, of the weight and of total serum lipids level.

Authors’ Affiliations

(1)
Psychiatric Department of Asklepeion General Hospital

References

  1. Meltezer H.Y., Bastani B.: Effect of six months of Clozapine Treatment on the Quality of life of chronic Schizophrenia patients. Hosp comm. Psychiatry. 1990, 41: 892-897.Google Scholar
  2. Goldstein L., Sporn J.: New-onset diabetes mellitus and diabetic Ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999, 40: 438-443.View ArticlePubMedGoogle Scholar
  3. Mukherzer S., Roth S, Sandyc R.: Persistent Tardivo dyskinesia and Neuroleptic effects on glucose tolerance. Psychiatry res. 1989, 29: 17-27. 10.1016/0165-1781(89)90183-2.View ArticleGoogle Scholar

Copyright

© Istikoglou et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement